The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index; 127 of the 159 sources its claims cite were checked for support.
Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance
Open accessAbstract
Review of antifungal heteroresistance as a reversible minority subpopulation phenomenon distinct from tolerance and persistence, with clinical implications for survival and treatment failure.
Overview
CoChat Summary
TL;DR
Antifungal heteroresistance is a reversible, often inducible phenotype in which a minority resistant fungal subpopulation coexists with a susceptible majority, complicating susceptibility testing and treatment. This narrative review summarizes known mechanisms—especially aneuploidy/copy number variation and gene-expression changes—and clinical implications, while noting that fungal heteroresistance remains underexplored compared with bacterial heteroresistance.
Key findings
- Heteroresistance can involve resistant subpopulations as rare as one in one million cells and may cause treatment failure, breakthrough infection, relapse, or prophylaxis failure despite in vitro susceptibility.
- Aneuploidy and copy number variations are central mechanisms, with examples including chr5/ERG11/TAC1 in *C. albicans*, chrE in *N. glabrata*, chr1 disomy in *C. neoformans*, and cross-resistance to azoles and 5-FC after fluconazole exposure.
- Clinical impact is substantial: invasive fungal infection mortality ranges from 40% to 70% in candidiasis, 40% to 80% in cryptococcosis, and can exceed 90% in aspergillosis; untreated high-level heteroresistant brain-infected mice reached 100% 20-day mortality.
- Conventional MIC-based testing may miss heteroresistant subpopulations; population analysis profile (PAP) is recommended as the gold standard, with time-kill and single-cell assays as additional approaches. No approved first-line therapies exist, though combination therapy or dose escalation may help, and adding 5-FC or amphotericin B to fluconazole monotherapy has achieved up to 90% efficacy in some settings.
Methods
- Narrative review of antifungal heteroresistance, tolerance, and persistence, synthesizing mechanisms and clinical relevance.
- Literature identified through PubMed and Web of Science using keywords “antifungal heteroresistance,” “antifungal resistance,” “antifungal tolerance,” and “antifungal persistence”; articles from 1995 to 2025 were considered.
- Priority given to peer-reviewed research articles, reviews, and case reports relevant to clinical microbiology and antifungal therapy; non-English articles, conference abstracts, and studies with ambiguous definitions or lacking direct relevance were excluded.
Limitations
- Stated: fungal heteroresistance remains largely underexplored, most research focuses on azole resistance, clinically important mechanisms have not been studied in sufficient depth, and comparative studies and clinical trials remain limited.
- Stated: mechanisms of stress induction and the genes involved in some heteroresistance phenotypes need further exploration.
- Evident from the text: as a narrative review, it does not provide a systematic quantitative synthesis or meta-analysis, and it notes ongoing definitional overlap between heteroresistance, tolerance, and persistence in the literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Antifungal mode of action of azoles, AMB, 5-FC and echinocandins. Azoles inhibit ergosterol biosynthesis by targeting sterol 14α-demethylase, producing toxic 14-methyl sterols, altering fungal cell membrane permeability and metabolic state [74,75]. Echinocandins target β-1,3-glucan synthase, impairing fungal cell wall integrity and stress resistance [76]. Amphotericin B binds to membrane ergosterol, forming pores that disrupt permeability and cause reactive oxygen species (ROS) accumulation, leading to cell death [77,78,79]. 5-FC is converted intracellularly to 5-FU, inhibiting DNA and RNA synthesis [80,81].](/paper-figures/ff01be48efb7424f88ea0cf1437ad8b2/insight-into-the-mechanisms-and-clinical-relevance-of-antifungal-figure-1.jpg)

Verification
Claims the paper makes
90 Valid · 4 Not valid · 14 Not checked · 28 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Bosch et al. demonstrated that environmental stress, such as the nitrogen limitation commonly encountered in its natural habitats, increases the resistance of C. neoformans to AmB and fluconazole, and increases the frequency of heterogeneous resistance to fluconazole [57].”
§ Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance > 7. Mechanisms of Antifungal Heteroresistance > 7.3. Environmental Stress Induction
What the sources say
- Disputedcites [57] Bosch, 2020, Nitrogen concentration affects amphotericin B and fluconazole tolerance of pathogenic cryptococci, FEMS Yeast Res. sourceExperimental — accuracy not yet measured
The ‘Frequency of fluconazole heteroresistance/tolerance’ section reports a higher combined frequency under low nitrogen, but identifies only C. gattii CAB 761 as heteroresistant. It classifies the tested C. neoformans strains as fluconazole-tolerant, not heteroresistant. No page number is available in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For example it was found that C. neoformans heteroresistance was detected at 35 °C but not at 30 °C, indicating the importance of environmental temperature [19].”
§ Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance > 7. Mechanisms of Antifungal Heteroresistance > 7.3. Environmental Stress Induction
What the sources say
- Disputedcites [19] Yamazumi, 2003, Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans, J. Clin. Microbiol. sourceExperimental — accuracy not yet measured
The Results state the opposite of the cited claim: heteroresistance was absent at 35°C and demonstrable only at 30°C in agar-based tests. The paper's opening summary reports the same temperature dependence. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For example it was found that C. neoformans heteroresistance was detected at 35 °C but not at 30 °C, indicating the importance of environmental temperature [19].”
§ Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance > 7. Mechanisms of Antifungal Heteroresistance > 7.3. Environmental Stress Induction
What the sources say
- Disputedcites [19] Yamazumi, 2003, Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans, J. Clin. Microbiol. sourceExperimental — accuracy not yet measured
The Results section reports the opposite temperature pattern: heteroresistance was absent at 35°C and demonstrable only at 30°C in agar-based tests. The Discussion confirms that incubation temperature affected the phenotype, but the citing sentence reverses the study’s finding. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, some 5–90% of the tolerant cells can slowly proliferate [105].”
§ Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance > 4. Heteroresistance, Tolerance and Persistence of Antifungal Drugs
What the sources say
- Partly supportedcites [105] Berman, 2020, Drug resistance and tolerance in fungi, Nat. Rev. Microbiol. sourceExperimental — accuracy not yet measured
The Introduction says that slowly growing tolerant cells make up 5–90% of all cells in an isolate, depending on the isolate. The citing sentence instead makes 5–90% a fraction of the tolerant cells, changing the denominator. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Repeated culture in stress-free environments can abolish heteroresistance [48].”
§ Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance > 4. Heteroresistance, Tolerance and Persistence of Antifungal Drugs
What the sources say
- Partly supportedcites [48] Ferreira, 2015, Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii, Antimicrob. Agents Chemother. sourceExperimental — accuracy not yet measured
The Results report that highly resistant C. gattii subclones returned to their initial itraconazole susceptibility after 10 subcultures in drug-free medium. But the paper also says the original strains exhibited heteroresistance, so the experiment shows loss of the elevated resistance level, not abolition of heteroresistance altogether. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
86 more claims · 62 with their cited sources checked
Create a free account to see all 136 claims and every source verdict.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In multiple murine infection models, Heteroresistant strains can lead to increased fungal burden and reduced treatment efficacy [28,29].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“This reproducible rebound trajectory provides direct evidence that the HR subpopulation is not merely tolerant but can proliferate under ongoing drug pressure [8]”
From Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in Candida Glabrata (2026) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance > 3. Antifungal Resistance Mechanisms
“Once inside the cell, 5-FC is converted to 5-fluorouracil (5-FU) through the action of cytosine deaminase and uracil phosphoribosyl transferase, both encoded by the FCY1 gene, inhibiting DNA and RNA biosynthesis [80,81].”
§ Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance > 3. Antifungal Resistance Mechanisms
“FCY1 encoding the cytosine deaminase, FUR1 encoding the uracil phosphoribosyl transferase”
Citations
Cites
Persister cells, dormancy and infectious disease
Lewis, K. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1557 · Cited by 2,052 · cited 1×
“Persistence is always linked to cell dormancy, a state in which the cellular metabolism temporarily ceases [111,123,124].”
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858 · cited 1×
“Persistence is always linked to cell dormancy, a state in which the cellular metabolism temporarily ceases [111,123,124].”
Global incidence and mortality of severe fungal disease
Denning, D. W. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00692-8 · Cited by 1,640 · cited 2×
“Fungi are signi fi cant eukaryotic pathogens in humans capable of causing infections ranging from super fi cial to life-threatening systemic diseases [8,31–40].”
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2018) · Science · doi:10.1126/science.aap7999 · Cited by 1,555
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Garcia-Vidal, C., Sanjuan, G., Moreno-García, E., Puerta-Alcalde, P., Garcia-Pouton, N., Chumbita, M., Fernandez-Pittol, M., Pitart, C., Inciarte, A., Bodro, M., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.041 · Cited by 1,022
Aneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733 · cited 3×
“By altering gene dosage or expression levels, aneuploidy allows fungi to quickly adjust to adverse conditions without permanent genetic mutations, promoting survival in fluctuating environments [99,129,145,152,154].”
Resistance of Candida to azoles and echinocandins worldwide
Pristov, K. E., & Ghannoum, M. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.028 · Cited by 706
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642 · cited 1×
“Furthermore, some 5–90% of the tolerant cells can slowly proliferate [105].”
Urease as a Virulence Factor in Experimental Cryptococcosis
Cox, G. M., Mukherjee, J., Cole, G. T., Casadevall, A., & Perfect, J. R. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.443-448.2000 · Cited by 522 · cited 2×
“…adaptation to changing pH conditions and nutrient availability [45,47,52–67], tissue invasions [40,42–44, Their pathogenicity stems from immune evasion [41–51], adaptation to changing pH conditions and nutrient availability [45,47,52–67], tissue invasions [40,42–44, 68, 68, 69] 69 , ], etc. etc.”
Cited by
Understanding the mechanisms of resistance to azole antifungals in Candida species
Li, Y., Hind, C. K., Furner-Pardoe, J., Sutton, J. M., & Rahman, K. M. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf106 · Cited by 74
Self-citationPublic Health Risks of Pathogenic Fungi in China
Miao, B., Yao, J., Zhang, S., Guo, X., Geng, Y., & Gong, J. (2026) · iFungi · doi:10.26599/ifungi.2026.9670003 · Cited by 19
Antifungal persistence: Clinical relevance and mechanisms
Wang, R., Lv, J., Chen, L., Zhao, Y., & Du, H. (2025) · PLoS pathogens · doi:10.1371/journal.ppat.1013456 · Cited by 12
Ferrara, G. A., Spruijtenburg, B., Meijer, E. F. J., Meis, J. F. G. M., Ceballos-Garzón, A., & Cáceres, D. H. (2025) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2025.100745 · Cited by 8
Harrington, A. A., Nickels, T. J., & Cunningham, K. W. (2026) · mBio · doi:10.1128/mbio.02546-25 · Cited by 4
Metadata
- Authors
- Su, Y., Li, Y., Yi, Q., Xu, Y., Sun, T., & Li, Y.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Sun, Tianshu
- Li, Yingxing
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2025-02-13
- Volume
- 11
- Issue
- 2
- Pages
- 143
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC11856953
- OpenAlex
- W4407526169
- Cited by
- 18
- References
- 180
- Citations by year
- 2026: 12 · 2025: 6
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National High Level Hospital Clinical Research Funding (2022-PUMCH-C-052)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- antifungal resistance, fungal pathogens, drug tolerance, fungal persistence, susceptibility testing, treatment failure, recurrent fungal infection, immunocompromised patients, antifungal therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance. https://app.cochat.ai/papers/10.3390/jof11020143
- The paper
- Su, Y., Li, Y., Yi, Q., Xu, Y., Sun, T., & Li, Y. (2025). Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance. Journal of Fungi. https://doi.org/10.3390/jof11020143
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.